Live Updates: COVID-19 Cases
  • World 30,530,546
    World
    Confirmed: 30,530,546
    Active: 7,372,165
    Recovered: 22,205,470
    Death: 952,911
  • USA 6,893,538
    USA
    Confirmed: 6,893,538
    Active: 2,521,105
    Recovered: 4,169,816
    Death: 202,617
  • India 5,274,606
    India
    Confirmed: 5,274,606
    Active: 1,020,825
    Recovered: 4,168,679
    Death: 85,102
  • Brazil 4,466,828
    Brazil
    Confirmed: 4,466,828
    Active: 578,543
    Recovered: 3,753,082
    Death: 135,203
  • Russia 1,091,186
    Russia
    Confirmed: 1,091,186
    Active: 170,784
    Recovered: 901,207
    Death: 19,195
  • Peru 750,098
    Peru
    Confirmed: 750,098
    Active: 124,439
    Recovered: 594,513
    Death: 31,146
  • Mexico 684,113
    Mexico
    Confirmed: 684,113
    Active: 123,518
    Recovered: 488,416
    Death: 72,179
  • South Africa 655,572
    South Africa
    Confirmed: 655,572
    Active: 54,497
    Recovered: 585,303
    Death: 15,772
  • Spain 654,637
    Spain
    Confirmed: 654,637
    Active: 624,232
    Recovered: ?
    Death: 30,405
  • Chile 442,827
    Chile
    Confirmed: 442,827
    Active: 14,647
    Recovered: 415,981
    Death: 12,199
  • Iran 416,198
    Iran
    Confirmed: 416,198
    Active: 36,741
    Recovered: 355,505
    Death: 23,952
  • France 415,481
    France
    Confirmed: 415,481
    Active: 293,546
    Recovered: 90,840
    Death: 31,095
  • UK 385,936
    UK
    Confirmed: 385,936
    Active: 344,204
    Recovered: ?
    Death: 41,732
  • Bangladesh 345,805
    Bangladesh
    Confirmed: 345,805
    Active: 88,589
    Recovered: 252,335
    Death: 4,881
  • Saudi Arabia 328,720
    Saudi Arabia
    Confirmed: 328,720
    Active: 15,938
    Recovered: 308,352
    Death: 4,430
  • Pakistan 304,386
    Pakistan
    Confirmed: 304,386
    Active: 6,295
    Recovered: 291,683
    Death: 6,408
  • Turkey 299,810
    Turkey
    Confirmed: 299,810
    Active: 27,628
    Recovered: 264,805
    Death: 7,377
  • Italy 294,932
    Italy
    Confirmed: 294,932
    Active: 42,457
    Recovered: 216,807
    Death: 35,668
  • Germany 270,653
    Germany
    Confirmed: 270,653
    Active: 19,890
    Recovered: 241,300
    Death: 9,463
  • Canada 141,565
    Canada
    Confirmed: 141,565
    Active: 8,852
    Recovered: 123,512
    Death: 9,201
  • Netherlands 90,047
    Netherlands
    Confirmed: 90,047
    Active: 83,774
    Recovered: ?
    Death: 6,273
  • China 85,255
    China
    Confirmed: 85,255
    Active: 165
    Recovered: 80,456
    Death: 4,634
  • Australia 26,861
    Australia
    Confirmed: 26,861
    Active: 2,169
    Recovered: 23,855
    Death: 837
  • S. Korea 22,783
    S. Korea
    Confirmed: 22,783
    Active: 2,635
    Recovered: 19,771
    Death: 377
  • New Zealand 1,809
    New Zealand
    Confirmed: 1,809
    Active: 70
    Recovered: 1,714
    Death: 25

Moderna vaccine candidate protects mice from COVID-19: Study

Author at TechGenyz Health
COVID-19 on Mice
A picture of 2 men walking with 2 dogs credit: @zhugher | Pixabay

US biotechnology company’s vaccine candidate protected mice from infection with SARS-CoV-2, the virus that causes COVID-19, according to a study published in the journal Nature on Wednesday.

The findings by scientists, including those from the National Institute of Allergy and Infectious Diseases (NIAID) in the US, show that the vaccine, known as mRNA-1273, induced neutralising antibodies in mice when given as two intramuscular injections of a 1-microgramme (mcg) dose three weeks apart.

Additional experiments found that mice given two injections of the 1-mcg dose and later challenged with SARS-CoV-2 virus either five or 13 weeks after the second injection were protected from viral replication in the lungs and nose, the researchers said.

Mice challenged seven weeks after only a single dose of 1 mcg or 10 mcg of mRNA-1273 were also protected against viral replication in the lung, they said.

NIAID Vaccine Research Center (VRC) scientists worked with investigators from the University of Texas at Austin to identify the atomic structure of the spike protein on the surface of the novel coronavirus.

This structure was used by Moderna in the development of the vaccine candidate, according to the researchers.

The latest study found that the investigational vaccine also induced robust CD8 T-cell responses in mice.

It did not induce the type of cellular immune response that has been linked to vaccine-associated enhanced respiratory disease (VAERD), according to the researchers.

This rare, allergic-type inflammation was seen in individuals vaccinated with a whole-inactivated respiratory syncytial virus (RSV) vaccine in the 1960s, they said.

The researchers explained that VAERD can occur when a vaccine induces an immune response that is not strong enough to protect against infection.

They vaccinated mice with sub-protective doses of mRNA-1273 and then challenged the mice with SARS-CoV-2.

The mice showed no evidence of enhanced lung pathology or excessive mucus production, indicating the vaccine did not cause enhanced disease, the researchers found.

The team noted that the data from these studies, combined with data from studies in nonhuman primates and Phase-1 clinical testing, support the evaluation of mRNA-1273 in clinical efficacy trials.

The researchers also explained how their prior research on a candidate MERS-CoV vaccine paved the way for a rapid response to the COVID-19 outbreak.

Career

Subscribe